1. From the Ludwig Center, Dana-Farber/Harvard Cancer Center, and Harvard Medical School, Boston, MA; Oncology Business Unit, Novartis Pharmaceuticals Corp, Florham Park, NJ; Oncology Business Unit and Biostatistics, Novartis Pharmaceuticals AG, Basel, Switzerland; British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; and Fox Chase Cancer Center, Philadelphia, PA.